Form 20-F þ | Form 40-F o |
Yes o | No þ |
Page | ||||
Part I FINANCIAL INFORMATION |
||||
Item 1. Condensed Consolidated Financial Statements (Unaudited) |
||||
a) Condensed Consolidated Statement of Operations for the
three months ended June 30, 2007 and 2006 |
2 | |||
a) Condensed Consolidated Statement of Operations for the
six months ended June 30, 2007 and 2006 |
3 | |||
b) Condensed Consolidated Balance Sheet as of
June 30, 2007 and December 31, 2006 |
4 | |||
c) Condensed Consolidated Statement of Cash Flows for the
six months ended June 30, 2007 and 2006 |
5 | |||
d) Consolidated Statement of Shareholders Equity for the
six months ended June 30, 2007 |
6 | |||
e) Notes to Condensed Consolidated Financial Statements |
7 | |||
Item 2. Managements Discussion and Analysis of
Financial Condition and Results of Operations |
10 | |||
PART II OTHER INFORMATION |
||||
Item 1. Legal Proceedings |
12 | |||
Item 1a. Risk Factors |
12 | |||
Item 4.
Submission of Matters to a Vote of Security Holders |
13 |
1
Three months ended June 30, | ||||||||
2006 | 2007 | |||||||
Revenue: |
||||||||
License and research revenue |
$ | 4,550 | $ | 1,794 | ||||
Product sales and services |
| 4,818 | ||||||
Other revenues |
185 | 837 | ||||||
Total revenue |
4,735 | 7,449 | ||||||
Costs and expenses: |
||||||||
Cost of goods and services sold |
(1,204 | ) | (3,699 | ) | ||||
Research and development |
(9,010 | ) | (13,204 | ) | ||||
Selling, general and administrative |
(4,106 | ) | (4,553 | ) | ||||
Total |
(14,320 | ) | (21,456 | ) | ||||
Profit (loss) from operations |
(9,585 | ) | (14,007 | ) | ||||
Interest income net |
488 | 437 | ||||||
Foreign exchange gain (loss) |
(282 | ) | (64 | ) | ||||
Other income (loss) |
(80 | ) | 33 | |||||
Income (loss) before income taxes |
(9,459 | ) | (13,601 | ) | ||||
Income tax benefit (expense) |
(9 | ) | (32 | ) | ||||
Net income (loss) |
$ | (9,468 | ) | $ | (13,633 | ) | ||
Earnings (loss) per share |
||||||||
Basic earnings (loss) per ordinary share |
$ | (0.40 | ) | $ | (0.57 | ) | ||
Diluted earnings (loss) per share |
$ | (0.40 | ) | $ | (0.57 | ) | ||
Weighted average number of shares outstanding (in thousands) : |
||||||||
Basic |
23,768 | 24,005 | ||||||
Diluted |
23,768 | 24,005 |
2
Six months ended June 30, | ||||||||
2006 | 2007 | |||||||
Revenue: |
||||||||
License and research revenue |
$ | 9,401 | $ | 4,918 | ||||
Product sales and services |
19 | 10,218 | ||||||
Other revenues |
413 | 1,938 | ||||||
Total revenue |
9,833 | 17,074 | ||||||
Costs and expenses: |
||||||||
Cost of goods and services sold |
(3,053 | ) | (8,179 | ) | ||||
Research and development |
(18,483 | ) | (23,758 | ) | ||||
Selling, general and administrative |
(8,025 | ) | (8,663 | ) | ||||
Total |
(29,561 | ) | (40,600 | ) | ||||
Profit (loss) from operations |
(19,728 | ) | (23,526 | ) | ||||
Interest income net |
939 | 894 | ||||||
Foreign exchange gain (loss) |
(399 | ) | (82 | ) | ||||
Other income (loss) |
93 | 38 | ||||||
Income (loss) before income taxes |
(19,095 | ) | (22,676 | ) | ||||
Income tax benefit (expense) |
(34 | ) | (18 | ) | ||||
Net income (loss) |
$ | (19,129 | ) | $ | (22,694 | ) | ||
Earnings (loss) per share |
||||||||
Basic earnings (loss) per ordinary share |
$ | (0.80 | ) | $ | (0.95 | ) | ||
Diluted earnings (loss) per share |
$ | (0.80 | ) | $ | (0.95 | ) | ||
Weighted average number of shares outstanding (in thousands) : |
||||||||
Basic |
23,768 | 24,005 | ||||||
Diluted |
23,768 | 24,005 |
3
December 31, | June 30, | |||||||
2006 | 2007 | |||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 51,827 | $ | 36,820 | ||||
Marketable securities |
10,944 | 10,145 | ||||||
Accounts receivable |
5,583 | 6,922 | ||||||
Inventory |
3,332 | 3,064 | ||||||
Research and development tax credit receivable short term |
615 | 631 | ||||||
Prepaid expenses and other current assets |
4,478 | 5,086 | ||||||
Total current assets |
76,779 | 62,668 | ||||||
Property and equipment, net |
25,705 | 31,013 | ||||||
Other assets: |
||||||||
Research and development tax credit receivable long term |
11,599 | 11,908 | ||||||
Other long-term assets |
811 | 846 | ||||||
Total other assets |
12,410 | 12,754 | ||||||
Total assets |
$ | 114,894 | $ | 106,435 | ||||
LIABILITIES |
||||||||
Current liabilities: |
||||||||
Current portion of capital lease obligations |
420 | 336 | ||||||
Accounts payable |
9,702 | 13,071 | ||||||
Current portion of deferred revenue |
562 | 136 | ||||||
Advances from customers |
394 | 748 | ||||||
Accrued expenses |
5,505 | 5,684 | ||||||
Other current liabilities |
4,731 | 5,049 | ||||||
Total current liabilities |
21,314 | 25,024 | ||||||
Long-term debt, less current portion |
2,795 | 2,866 | ||||||
Capital lease obligations, less current portion |
272 | 157 | ||||||
Deferred revenue, less current portion |
50 | | ||||||
Other long-term liabilities |
17,437 | 19,403 | ||||||
Total long-term liabilities |
20,554 | 22,426 | ||||||
Commitments and contingencies: |
| | ||||||
Shareholders equity: |
||||||||
Ordinary shares : 23,990,590 issued and outstanding at December 31, 2006 and
24,041,590 at June 30, 2007 |
3,480 | 3,488 | ||||||
Additional paid-in capital |
173,479 | 180,192 | ||||||
Accumulated deficit |
(110,384 | ) | (133,078 | ) | ||||
Deferred compensation |
| |||||||
Accumulated other comprehensive income (loss) |
6,451 | 8,383 | ||||||
Total shareholders equity |
73,026 | 58,985 | ||||||
Total liabilities and shareholders equity |
$ | 114,894 | $ | 106,435 | ||||
4
Six months ended June 30, | ||||||||
2006 | 2007 | |||||||
Cash flows from operating activities: |
||||||||
Net income (loss) |
($19,129 | ) | ($22,694 | ) | ||||
Adjustments to reconcile net income (loss)
to net cash provided by (used in) operating activities: |
||||||||
Depreciation of property and equipment |
2,431 | 3,004 | ||||||
Gain (loss) on disposal of property and equipment |
(2 | ) | (11 | ) | ||||
Gains on sales of marketable securities |
(895 | ) | (114 | ) | ||||
Stock compensation expense |
4,366 | 6,504 | ||||||
Increase (decrease) in cash from: |
||||||||
Accounts receivable |
(3,040 | ) | (1,177 | ) | ||||
Prepaid expenses and other current assets |
1,032 | (140 | ) | |||||
Research and development tax credit receivable |
771 | (14 | ) | |||||
Accounts payable |
(4,825 | ) | 1,667 | |||||
Deferred revenue |
76 | (484 | ) | |||||
Accrued expenses |
(345 | ) | 376 | |||||
Other current liabilities |
(2,035 | ) | (843 | ) | ||||
Other long-term assets and liabilities |
1,811 | (357 | ) | |||||
Net cash provided by (used in) operating activities |
(20,177 | ) | (14,283 | ) | ||||
Cash flows from investing activities: |
||||||||
Purchases of property and equipment |
(1,866 | ) | (6,186 | ) | ||||
Proceeds from disposal of property and equipment |
2 | 14 | ||||||
Purchase of marketable securities |
(136,746 | ) | (50,158 | ) | ||||
Proceeds from sales of marketable securities |
162,378 | 51,349 | ||||||
Net cash provided by (used in) investing activities |
23,768 | (4,981 | ) | |||||
Cash flows from financing activities: |
||||||||
Funding from partner GSK |
| 2,745 | ||||||
Use of funds received from partners (GSK) or relating to conditional grants |
(531 | ) | | |||||
Proceeds from loans or conditional grant |
200 | 133 | ||||||
Principal payments on capital lease obligations |
(192 | ) | (213 | ) | ||||
Cash proceeds from issuance of ordinary shares and warrants |
1,195 | 528 | ||||||
Net cash provided by financing activities |
672 | 3,193 | ||||||
Effect of exchange rate changes on cash and cash equivalents |
263 | 1,064 | ||||||
Net increase (decrease) in cash and cash equivalents |
4,526 | (15,007 | ) | |||||
Cash and cash equivalents, beginning of the period |
1,018 | 51,827 | ||||||
Cash and cash equivalents, end of the period |
$ | 5,544 | $ | 36,820 | ||||
5
Accumulated | ||||||||||||||||||||||||
Other | ||||||||||||||||||||||||
Additional | Comprehen- | |||||||||||||||||||||||
Ordinary Shares | Paid-in | Accumulated | sive Income | Shareholders | ||||||||||||||||||||
Shares | Amount | Capital | Deficit | (Loss) | Equity | |||||||||||||||||||
Balance at January 1, 2007 |
23,990,590 | $ | 3,480 | $ | 173,479 | $ | (110,384 | ) | $ | 6,451 | $ | 73,026 | ||||||||||||
Subscription of warrants |
362 | 362 | ||||||||||||||||||||||
Issuance of ordinary shares on exercise of
stock -options |
51,000 | 8 | 158 | 166 | ||||||||||||||||||||
Stock-based compensation expense |
6,193 | 6,193 | ||||||||||||||||||||||
Net loss |
(22,694 | ) | (22,694 | ) | ||||||||||||||||||||
Unrealized losses on available-for-sale
securities |
17 | 17 | ||||||||||||||||||||||
Foreign currency translation
adjustment |
1,915 | 1,915 | ||||||||||||||||||||||
Comprehensive loss |
$ | (20,762 | ) | |||||||||||||||||||||
Balance at June 30, 2007 |
24,041,590 | $ | 3,488 | $ | 180,192 | $ | (133,078 | ) | $ | 8,383 | $ | 58,985 | ||||||||||||
6
7
(In thousands of U.S. dollars) | December 31, 2006 | June 30, 2007 | ||||||
Raw materials |
1,752 | 2,064 | ||||||
Finished goods |
1,752 | 1,846 | ||||||
Provision for inventory obsolescence |
(172 | ) | (846 | ) | ||||
Inventories, net |
3,332 | 3,064 | ||||||
8
Three months ended | ||||
June 30, 2007 | ||||
Risk-free interest rate |
4.99 | % | ||
Dividend yield |
| |||
Expected volatility |
51 | % | ||
Expected term |
0.92 | |||
Forfeiture rate |
|
Three months ended | Six months ended | |||||||||||||||
June 30, | June 30, | June 30, | June 30, | |||||||||||||
(in thousands except per share data) | 2006 | 2007 | 2006 | 2007 | ||||||||||||
Net loss |
(9,468 | ) | (13,633 | ) | (19,129 | ) | (22,694 | ) | ||||||||
Net loss per share |
||||||||||||||||
Basic |
$ | (0.40 | ) | $ | (0.57 | ) | $ | (0.80 | ) | $ | (0.95 | ) | ||||
Diluted |
$ | (0.40 | ) | $ | (0.57 | ) | $ | (0.80 | ) | $ | (0.95 | ) | ||||
Number of shares used for computing |
||||||||||||||||
Basic |
23,768 | 24,005 | 23,768 | 24,005 | ||||||||||||
Diluted |
23,768 | 24,005 | 23,768 | 24,005 | ||||||||||||
Stock-based compensation (FAS123R) |
||||||||||||||||
Cost of products and services sold |
24 | 112 | 58 | 225 | ||||||||||||
Research and development |
686 | 1,506 | 1,667 | 3,107 | ||||||||||||
Selling, General and administrative |
1,323 | 1,530 | 2,637 | 3,172 | ||||||||||||
Total |
2,033 | 3,148 | 4,362 | 6,504 | ||||||||||||
Net income (loss) before stock-based
compensation |
(7,435 | ) | (10,485 | ) | (14,767 | ) | (16,190 | ) | ||||||||
Net income (loss) before stock-based
compensation per share |
||||||||||||||||
Basic |
$ | (0.31 | ) | $ | (0.47 | ) | $ | (0.62 | ) | $ | (0.67 | ) | ||||
Diluted |
$ | (0.31 | ) | $ | (0.47 | ) | $ | (0.62 | ) | $ | (0.67 | ) |
9
10
11
| our product candidates, if approved for marketing, may not produce significant revenues and we rely on our partners to determine the regulatory and marketing strategies; | ||
| our product candidates, in commercial use, may have unintended side effects, adverse reactions or incidents of misuse; | ||
| we may enter into a collaboration with a third party to market or fund a proprietary product candidate and the terms of such a collaboration may not meet our expectations; | ||
| our delivery technologies or product development efforts may not produce safe, effective or commercially viable products; | ||
| our collaborators could elect to terminate or delay programs at any time and disputes with collaborators or failure to negotiate acceptable new collaborative arrangements for our technologies could occur; | ||
| we may be unable to manufacture or, if our products are successful, scale-up the manufacturing of our products economically or on a commercial scale; | ||
| unexpected events could interrupt manufacturing operations at our facilities, which could be the sole source of supply for these products; | ||
| after the completion of clinical trials of products incorporating our technologies and the submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA), for marketing approval and to other health authorities as a marketing authorization application, the FDA or other health authorities could refuse to accept such filings or could request additional pre-clinical or clinical studies be conducted, each of which could result in significant delays, or such authorities could refuse to approve the product at all; | ||
| our product candidates could be ineffective or unsafe during pre-clinical studies and clinical trials and we and our collaborators may not be permitted by regulatory authorities to undertake new or additional clinical trials for product candidates incorporating our technologies, or clinical trials could be delayed; | ||
| we may experience significant delays in clinical trials on our products; | ||
| we may not realize any revenue from milestone or royalty payments under our license agreements with our partners, including GlaxoSmithKline; | ||
| even if our product candidates appear promising at an early stage of development, product candidates could fail to receive necessary regulatory approvals, be difficult to manufacture on a large scale, be uneconomical, fail to achieve market acceptance, be precluded from |
12
commercialization by proprietary rights of third parties or experience substantial competition in the marketplace; | |||
| technological changes in the biotechnology or pharmaceutical industries could render our product candidates obsolete or noncompetitive; | ||
| we may face difficulties or set-backs in obtaining and enforcing our patents or defending claims of patent infringement by others; | ||
| we may need to raise substantial additional funding to continue research and development programs and clinical trials and could incur difficulties or setbacks in raising such funds; and |
For | Against | |||||||
1. Approval of Statutory Accounts for year ended 31 December 2006. |
23 620 917 | 285 003 | ||||||
2. Allocation of results to retained earnings. |
23 727 789 | 178 131 | ||||||
3. Renewal of Mr Elie Vannier as Director. |
23 724 329 | 181 591 | ||||||
4. Renewal of Mr Cor Boonstra as Director. |
23 670 841 | 235 079 | ||||||
5. Renewal of Mr. Frederic Lemoine as Director. |
23 707 906 | 198 014 | ||||||
6. Renewal of Mr. John L. Vogelstein as Director. |
23 730 689 | 175 231 | ||||||
7. Renewal of Mr. Stephen H. Willard as Director. |
23 706 812 | 199 108 | ||||||
8. Renewal of Mr Lodewijk J.R. De Vink as Director. |
23 727 307 | 178 613 | ||||||
9. Determination of the annual amount of Directors attendance fees. |
23 738 516 | 167 404 | ||||||
10. Approval of agreements referred to in article L. 225-38 et seq.
of the Commercial Code. |
23 593 557 | 312 363 | ||||||
11. Authorization for Stock Option Plan of five hundred thousand
(500,000) stock options. |
23 340 183 | 565 738 |
13
For | Against | |||||||
12. Authorization for issuance of two hundred
thousand (200,000) shares at no cost (free
shares). |
23 070 394 | 835 526 | ||||||
13. Authorization for issuance of one hundred
and fifty thousand (150,000) stock warrants
(BSA). |
23 091 273 | 814 647 | ||||||
14. Authorization to increasing the share
capital by issues of shares reserved for the
members of a company saving plan established in
application of Articles L.443-5 et seq. of the
Labour Code. |
509 843 | 23 396 077 |
14
Flamel Technologies | ||||
Dated:
September 4, 2007
|
/s/ Stephen H. Willard | |||
Chief Executive Officer |
15